Description: Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Home Page: www.enlivex.com
14 Einstein Street
Ness Ziona,
7403618
Israel
Phone:
972 8 662 3301
Officers
| Name | Title |
|---|---|
| Mr. Shai Novik M.B.A. | Exec. Chairman |
| Dr. Oren Hershkovitz Ph.D. | Chief Exec. Officer |
| Prof. Dror Mevorach M.D. | Founder and Chief Scientific & Medical Officer |
| Ms. Shachar Shlosberger CPA | Chief Financial Officer |
| Ms. Sigal Arad | Director of HR |
| Mr. Veronique Amor-Baroukh | Head Of CMC |
Exchange: TA
Country: IL : Israel
Currency: Israeli Agora (ILA)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2268 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 71 |